Professor Wang Changli is the former Vice President of the Cancer Hospital of Tianjin Medical University, the former Chairman of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association, the current Vice Chairman of the Tumor Special Committee for Capacity Building and Continuing Education of the National Health Commission, the Vice Chairman of the Non-Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), the Chairman of the Lung Cancer Professional Committee of the Tianjin Anti-Cancer Association, the Director of the Tianjin Lung Cancer Diagnosis and Treatment Center, the Director of the Surgery Teaching and Research Office of the Cancer Hospital of Tianjin Medical University, the Director of the Academic Committee of Hainan Cancer Hospital, and the specially appointed Director of the Thoracic Tumor Center.
Professor Wang Changli has been engaged in clinical, teaching, and research work in thoracic oncology for 40 years. He is a leader in the national key specialty of thoracic surgery, specializing in early diagnosis, surgical treatment, comprehensive treatment, and basic and clinical research related to lung cancer. He is skilled in handling various complex and difficult thoracic malignancy surgeries and has conducted years of continuous and systematic research on lymph node dissection in lung cancer surgery.
Professor Wang Changli, with his superb surgical skills and exceptional expertise, pioneered the use of artificial intelligence-assisted treatment technology (Da Vinci surgical robot platform for minimally invasive lung cancer surgery) in Tianjin, opening up a new field of surgical treatment for lung tumors. In 2020, he established the National Da Vinci Surgical Robot Lung Cancer Surgery Clinical Operation Teaching Demonstration Center, which covers more than 30 provinces and cities across the country. The center holds online live demonstrations of standardized robotic minimally invasive surgery and thoracoscopic surgery for lung cancer multiple times a year, significantly advancing the minimally invasive surgery technology for lung cancer in China.